The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Nplate 250 micrograms



Amgen Europe B.V.EU/1/08/497/1,3

Main Information

Trade NameNplate 250 micrograms
Active SubstancesRomiplostim
Dosage FormPowder for solution for injection
Licence HolderAmgen Europe B.V.
Licence NumberEU/1/08/497/1,3

Group Information

ATC CodeB02BX Other systemic hemostatics
B02BX04 romiplostim

Status

License statusAuthorised
Licence Issued11/01/2010
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

« Back